The Delhi High Court has rejected a trademark claim by Alkem Laboratories, a pharmaceutical company, over the use of the term “A TO Z” for its products. The court ruled that alphabets are public property and cannot be monopolized by a single entity. <\/p>\n
Alkem Laboratories had filed a lawsuit against another pharmaceutical company, Unichem Laboratories, alleging that Unichem’s use of the term “A TO Z” for its products infringed on Alkem’s trademark. Alkem claimed that it had been using the term “A TO Z” for its products since 1972 and had acquired a reputation and goodwill in the market.<\/p>\n
However, the court rejected Alkem’s claim, stating that alphabets are public property and cannot be trademarked. The court observed that the term “A TO Z” is a common phrase used to denote a comprehensive range of products or services, and its use by Unichem did not infringe on Alkem’s trademark.<\/p>\n
The court also noted that Alkem had not provided sufficient evidence to prove that its use of the term “A TO Z” had acquired a distinctive character and was exclusively associated with its products. The court held that the term “A TO Z” is a descriptive phrase and not a distinctive trademark.<\/p>\n
The judgment is significant as it sets a precedent for the use of common phrases and alphabets in trademarks. It emphasizes that companies cannot claim exclusive rights over public property, such as alphabets, and that trademark law is intended to protect distinctive signs and symbols that identify a particular business or product.<\/p>\n
The court’s decision is also a victory for Unichem Laboratories, which can continue to use the term “A TO Z” for its products without fear of infringement. The judgment highlights the importance of ensuring that trademark claims are not used to stifle competition or restrict the use of common language.<\/p>\n
In conclusion, the Delhi High Court’s rejection of Alkem’s trademark claim over the term “A TO Z” is a significant ruling that emphasizes the public nature of alphabets and common phrases. The judgment sets a precedent for the use of trademarks and highlights the importance of protecting distinctive signs and symbols that identify a particular business or product.<\/p>\n","protected":false},"excerpt":{"rendered":"
The Delhi High Court has rejected a trademark claim by Alkem Laboratories, a pharmaceutical company, over the use of the term “A TO Z” for its products. The court ruled that alphabets are public property and cannot be monopolized by a single entity. Alkem Laboratories had filed a lawsuit against another pharmaceutical company, Unichem Laboratories, […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[22,2],"tags":[],"class_list":["post-89849","post","type-post","status-publish","format-standard","hentry","category-alkem","category-pharma"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89827,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/20\/delhi-high-court-rejects-interim-injunction-rules-that-letters-a-and-z-are-not-exclusive-property\/","url_meta":{"origin":89849,"position":0},"title":"Delhi High Court Rejects Interim Injunction, Rules That Letters ‘A’ and ‘Z’ Are Not Exclusive Property.","author":"Team Small News","date":"January 20, 2026","format":false,"excerpt":"The Delhi High Court has made a significant ruling in a trademark infringement case, stating that the use of letters \"A\" and \"Z\" cannot be monopolized by a single entity. The court refused an interim injunction sought by a company that claimed exclusive rights to the use of these letters\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89838,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/22\/alkem-laboratories-slapped-with-%e2%82%b92-35-crore-gst-demand-notice-and-penalty-by-additional-commissioner-as-reported-by-scanx-trade\/","url_meta":{"origin":89849,"position":1},"title":"Alkem Laboratories slapped with \u20b92.35 crore GST demand notice and penalty by Additional Commissioner, as reported by scanx.trade","author":"Team Small News","date":"January 22, 2026","format":false,"excerpt":"Alkem Laboratories, a prominent Indian pharmaceutical company, has received a Goods and Services Tax (GST) demand order from the Additional Commissioner, totaling \u20b92.35 crore, along with a penalty. The order, which was issued on [date], has sparked concerns among the company's stakeholders and has the potential to impact its financial\u2026","rel":"","context":"In "Alkem"","block_context":{"text":"Alkem","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/alkem\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89836,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/22\/dr-reddys-relies-on-biosimilars-and-weight-loss-medication-launches-to-compensate-for-declining-us-dominance-of-revlimid\/","url_meta":{"origin":89849,"position":2},"title":"Dr Reddy’s relies on biosimilars and weight-loss medication launches to compensate for declining US dominance of Revlimid.","author":"Team Small News","date":"January 22, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories, a leading Indian pharmaceutical company, is shifting its focus towards biosimilars and a new weight-loss drug to drive growth as its exclusivity for the generic version of Revlimid in the US market is set to expire. Revlimid, a blood cancer treatment, has been a significant contributor to\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89809,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/16\/indian-pharma-q3-preview-strong-domestic-formulations-segment-to-offset-us-pricing-challenges-scanx-trade\/","url_meta":{"origin":89849,"position":3},"title":"Indian Pharma Q3 Preview: Strong Domestic Formulations Segment to Offset US Pricing Challenges – scanx.trade","author":"Team Small News","date":"January 16, 2026","format":false,"excerpt":"The Indian pharmaceutical industry is expected to experience a mixed bag in the third quarter of the year, with domestic formulations likely to counterbalance the pressure from pricing in the US market. The sector's growth is anticipated to be driven by a strong performance in the domestic market, which is\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":89810,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/16\/will-indian-pharmaceuticals-domestic-offerings-provide-a-buffer-against-pricing-pressures-from-the-us-market-in-the-third-quarter\/","url_meta":{"origin":89849,"position":4},"title":"Will Indian pharmaceuticals’ domestic offerings provide a buffer against pricing pressures from the US market in the third quarter?","author":"Team Small News","date":"January 16, 2026","format":false,"excerpt":"The Indian pharmaceutical industry is expected to have a mixed third quarter, with domestic formulations and specialty launches driving growth despite US pricing pressure. Companies like Sun Pharmaceuticals and Lupin are likely to lead the way, driven by their specialty businesses. Sun Pharma's revenue is expected to grow in the\u2026","rel":"","context":"In "Divi's Laboratories"","block_context":{"text":"Divi's Laboratories","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/divis-laboratories\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/divis-lab-logo.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":89802,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/15\/dr-reddys-introduces-generic-version-of-antihistamine-eye-drops-to-the-us-market\/","url_meta":{"origin":89849,"position":5},"title":"Dr Reddy’s introduces generic version of antihistamine eye drops to the US market","author":"Team Small News","date":"January 15, 2026","format":false,"excerpt":"Dr. Reddy's Laboratories has launched an over-the-counter (OTC) eye drop solution, Olopatadine Hydrochloride Ophthalmic Solution, in the US market. The solution is a generic equivalent of Extra Strength Pataday Once-Daily Relief, which is used to provide temporary relief from itchy eyes caused by pollen, ragweed, grass, animal hair, and dander.\u2026","rel":"","context":"In "Dr Reddy's"","block_context":{"text":"Dr Reddy's","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/dr-reddys\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/Dr.Reddys_logo.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89849"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89849\/revisions"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}